SLC5A2 and diabetes mellitus: Moreover, other factors should be considered for the risk of fractures with SGLT2 inhibitors, including the predisposition of patients with type 2 diabetes mellitus (53), and the absence of a pathogenetic mechanism linking the onset of fractures with the use of SGLT2 inhibitors (54).